Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy31

Select a period of time:

Views

Views
January 20253
February 20250
March 202515
April 20252
May 20251
June 20251
July 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United Kingdom4
United States2
Brazil1
Spain1
 

Top cities views

Views
London2
Council Bluffs1
Parnaíba1